Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sona Nanotech Inc C.SONA

Alternate Symbol(s):  SNANF

Sona Nanotech Inc. is a nanotechnology life sciences company, which is engaged in developing targeted hyperthermia therapy. The Company has developed multiple methods for the manufacturing of various types of gold nanoparticles (GNR). It is engaged in research and development of its technology for use in multiplex diagnostic testing platforms and advanced biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of cetyltrimethylammonium bromide (CTAB), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company is focused on the development of a pre-clinical nanomedical therapy for the treatment of cancer using its biocompatible GNR.


CSE:SONA - Post by User

Bullboard Posts
Post by alphaseeking001on Jul 13, 2020 5:20am
305 Views
Post# 31258985

Interesting... BOND digital health tweet this morning

Interesting... BOND digital health tweet this morning

Grants to aid Covid-19 test development

Grants to aid Covid-19 test development

Bond Digital Health has received more than £200,000 in government grants to help the medical technology business develop its connectivity and data platform for a new Covid-19 test.

The Cardiff-based company was awarded two major grants for itsTransform technology - including £177,979 from the Welsh Government and £49,796 from Innovate UK, the UK’s national innovation agency.

Bond is part of an international consortium that is producing a new diagnostic test for patients suspected of having Covid-19.

It applied for the grants to help support the ongoing development of Transform to meet the particular requirements of the new test. The Welsh Government provided funding through its COVID RD&I support scheme, while Innovate UK awarded funding through its Business-led Innovation in Response to Global Disruption competition.

Phil Groom, commercial director of Bond Digital Health, said: "These two grants represent a huge vote of confidence in our business and our technology from both the Welsh and UK governments.

"We are proud to be part of an international consortium whose test will make such a difference in this pandemic and even more proud to be flying the flag for Welsh technology and talent on the global stage."

Earlier this year Bond received equity funding totalling £700,000 from Development Bank of Walesand Wealth Club, the high net worth investment service, to expand the technology team and to speed up development.

Bullboard Posts